Canaccord analyst Kyle Mikson lowered the firm’s price target on Caris Life Sciences (CAI) to $22 from $30 and keeps a Hold rating on the shares. The firm said their target decrease is driven by reduced long-term estimates, supported by sector multiple compression and our review of volume trends in the tissue-based therapy selection testing market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences Signals Strong Growth and Ambition
- Caris Life Sciences price target raised to $28 from $26 at Baird
- Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI
- Caris Life Sciences price target lowered to $38 from $45 at BTIG
- Caris Life Sciences price target lowered to $35 from $40 at JPMorgan